The study explores whether and how lifetime violence exposure is related to a set of negative symptoms: child internalizing and externalizing behavior problems, child trauma symptoms, and parenting stress. Using a large sample of violence-exposed children recruited to participate in intervention research, the study employs different methods of measuring that exposure. These include total frequency of all lifetime exposure, total frequency of lifetime exposure by broad category (i.e., assault, maltreatment, sexual abuse, and witnessing violence), and polyvictimization defined as exposure to multiple violence categories. The results indicate that only polyvictimization, constructed as a dichotomous variable indicating two or more categories of lifetime exposure, emerged as a consistent predictor of negative symptoms. The total lifetime frequency of all violence exposure was not associated with negative symptoms, after controlling for the influence of polyvictimization. Likewise, in the presence of a dichotomous polyvictimization indicator the total lifetime frequency of exposure to a particular violence category was unrelated to symptoms overall, with the exception of trauma symptoms and experiences of sexual abuse. Taken together, these findings suggest that total lifetime exposure is not particularly important to negative symptoms, nor is any particular category of exposure after controlling for polyvictimization, with the single exception of sexual abuse and trauma symptoms. Instead, it is the mix of exposure experiences that predict negative impacts on children in this sample. Further research is needed to continue to explore and test these issues.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/0886260512468239 | DOI Listing |
Clin Genitourin Cancer
December 2024
Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT. Electronic address:
Background: Enfortumab vedotin (EV) is a nectin-4-directed antibody and microtubule inhibitor conjugate indicated for patients with metastatic urothelial carcinoma (mUC) who have received prior platinum-based chemotherapy and PD-1/L1 inhibitors or are ineligible for cisplatin-containing regimens and have undergone at least 1 prior line of therapy. EV is also indicated in combination with pembrolizumab in the first-line setting. However, real-world effectiveness of EV based on treatment line and impact of prior therapy remains unclear.
View Article and Find Full Text PDFMar Pollut Bull
December 2024
Suganthi Devadason Marine Research Institute, Tuticorin, Tamil Nadu, India. Electronic address:
Toxic metals pollution in the marine environment can lead to seafood contamination, affecting people's health. The objective of the present study was to determine the level of heavy metal contamination in the most common seafood and the health risks associated with its consumption in Thirespuram, Tuticorin. Samples were collected directly from the fishermen at the landing sites of the study area between October and December 2022.
View Article and Find Full Text PDFToxicol Rep
December 2024
Lancaster Environment Centre, Lancaster University, Lancaster LA1 4YQ, UK.
The use of pesticides in commercial farms can lead to exposure among various vulnerable groups. This study assessed the distribution, human health risks, and origins of 13 targeted organochlorine pesticides (OCPs) in soil samples from commercial farms in Southern Nigeria. Following a questionnaire survey on pesticide usage, soil samples were subjected to Soxhlet extraction and analyzed using gas chromatography-mass spectrometry.
View Article and Find Full Text PDFAJPM Focus
February 2025
NORC at the University of Chicago, Bethesda, Maryland.
Introduction: Guns were one of the leading causes of death in children and youth aged 0-24 years in the U.S. over the last decade, with large variations by sex, race, region, and income.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!